Senores Pharmaceuticals Limited - IPO

1. Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.

2. Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.

3. Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.

4. Presence in the Emerging Markets with a product portfolio, including specialty or complex products.

5. R&D capabilities driving our differentiated portfolio of products.

6. Professional management teams for our diverse business verticals.

1. Our business is dependent on the sale of our products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for our products or our inability to maintain and increase the number of our arrangements for the marketing and distribution of our products could adversely affect our business, results of operations, financial conditions and cash flows.

2. Our business is dependent on the sale of our products and continued growth of the Regulated Markets. Decrease in market growth for our product or failure to respond to change in market conditions could adversely affect our business, results of operations, financial conditions and cash flows.

3. Failure to comply with the quality standards and technical specifications prescribed by our customers may lead to loss of business from such customers and could negatively impact our business, results of operations and financial condition, including cancellation of existing and future orders which may expose us to warranty claims.

4. We derive a part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us or to terminate our contracts or purchase orders, our business, cash flows, financial condition and results of operations may be adversely affected.

5. We have had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on our business and operations.

6. The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose us to litigation or other liabilities, which could adversely affect our reputation, business, financial condition and results of operations. There have been instances in the past where our drugs failed to meet standards prescribed under applicable law and action was taken against us by regulatory authorities.

7. We derive a major portion of our revenue from our operations in the United States. A reduction in demand for our products in these regions could adversely affect our business, results of operations, financial conditions and cash flows.

8. Any manufacturing or quality control problems may damage our reputation for high quality production and expose us to potential litigation or other liabilities, which would negatively impact our business, prospects, results of operations and financial condition.

9. Some of our Directors and Promoters may have interest in entities, which are in businesses similar to ours and this may result in conflict of interest with us. Further, certain of our Promoter Group, Subsidiaries and Group Companies are in the same line of business as us, which may result in a conflict of interest.

10. The erstwhile statutory auditors of our Company have issued a qualified opinion in connection with their audit report for Fiscal 2022.